A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression
Phase of Trial: Phase III
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Esketamine (Primary) ; Duloxetine; Escitalopram; Sertraline; Venlafaxine
- Indications Depression; Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms TRANSFORM-1
- Sponsors Janssen Research & Development
- 22 Jul 2017 This trial has been discontinued in Poland
- 30 Aug 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Apr 2018.
- 09 Aug 2016 Planned End Date changed from 1 Oct 2017 to 1 Aug 2018.